Targeting Interleukin-4 Receptor Alpha by Hybrid Peptide for Novel Biliary Tract Cancer Therapy
Figure 4
Antitumor activity of IL-4Rα-lytic hybrid peptide in tumor xenograft model in vivo. TGBC-44-TKB were implanted subcutaneously into athymic nude mice. Intravenous injection of saline and IL-4Rα-lytic hybrid peptide (2 mg/kg or 5 mg/kg) is indicated by the arrows. Data are expressed as mean SD ( animals in each group).
